LONDON, June 1, 2021 /PRNewswire/ — Small Pharma Inc. (TSXV: DMT) (the “ Company” or “Small Pharma“), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announces the expansion of its Phase I/IIa clinical trial for its lead product, SPL026, a N,N-dimethyltryptamine (“DMT“) based treatment for major depressive disorder (“MDD“). Hammersmith Medicines Research is leading…


Previous articlePT246 – Amber and Marcus Capone of VETS – Foundational Healing and the Brain
Next articleCybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral Cortex Hemodynamics